Preparation and Evaluation of Medicated Formulation for Dry Eye

被引:0
作者
Singh N. [1 ]
Maurta R. [1 ,2 ]
Mishra S. [1 ,3 ]
Jain D. [1 ]
机构
[1] School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Madhya Pradesh
[2] National Ayurveda Research Institute for Panchakarma, CCRAS, Kerala, Cheruthuruthy
[3] Department of Pharmaceutical Sciences and Technology, Madan Mohan Malaviya University of Technology, Uttar Pradesh, Gorakhpur
关键词
carbowax; 1000; HET-CAM study; in vivo study; stability studies; Vapor pressure manometer; viscosity;
D O I
10.2174/2210681213666230526152322
中图分类号
学科分类号
摘要
Introduction: The current research involved the study of chondroitin sulfate polymer to prevent moisture loss, which was formulated to treat dry eye. Methods: The ophthalmic formulation was prepared with 5% liquid paraffin wax, 10% carbowax, and 1% glycerine. Furthermore, its usefulness in ophthalmology was analyzed by measuring parameters like pH, isotonicity, turbidity, viscosity, % moisture loss, vapor pressure, and in vitro and in vivo corneal damage. Results: We successfully adjusted the pH and osmolality of the F2 formulation to the desired physiological levels, providing the opportunity to reduce the harmful reaction as well as inflammation and dehydration. In addition, viscosity plays an important role in ophthalmic preparation. Consequently, the stability studies of optimized formulation indicated no remarkable changes in physical properties, including pH, viscosity, phase separation, and turbidity. Furthermore, a vapor pressure manometer studied the percentage of moisture loss. Interestingly, the HET-CAM test correlated properly with the findings of the Draize eye inflammation test. Moreover, the in vivo irritation test of the optimized system showed that it was tolerable, with no signs of irritation in the rabbit eye compared to the marketed formulation. In addition, the F2 formulation demonstrated better results than the marketed corneal preparation. Thereby, from the results, it can be concluded that the simple manometer apparatus can be the best method for evaluating moisture loss prevention for dry eyes. No study or investigation has been reported before for ophthalmic preparation. Conclusion: Altogether, chondroitin sulfate with carbowax 1000 and liquid paraffin-based ophthalmic preparation can be considered a promising approach for preventing dryness of the eye. © 2023 Bentham Science Publishers.
引用
收藏
页码:65 / 78
页数:13
相关论文
共 48 条
[1]  
Viso E., Gude F., Rodriguez-Ares M.T., The association of meibomian gland dysfunction and other common ocular diseases with dry eye: A population-based study in Spain, Cornea, 30, 1, pp. 1-6, (2011)
[2]  
Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC, The pathology of dry eye: The interaction between the ocular surface and lacrimal glands, Cornea, 17, 6, pp. 584-589, (1998)
[3]  
Goto E., Endo K., Suzuki A., Fujikura Y., Matsumoto Y., Tsubota K., Tear evaporation dynamics in normal subjects and subjects with obstructive meibomian gland dysfunction, Invest. Ophthalmol. Vis. Sci, 44, 2, pp. 533-539, (2003)
[4]  
Stern M.E., Gao J., Siemasko K.F., Beuerman R.W., Pflugfelder S.C., The role of the lacrimal functional unit in the pathophysiology of dry eye, Exp. Eye Res, 78, 3, pp. 409-416, (2004)
[5]  
Craig J.P., Nichols K.K., Akpek E.K., Caffery B., Dua H.S., Joo C.K., Liu Z., Nelson J.D., Nichols J.J., Tsubota K., Stapleton F., TFOS DEWS II definition and classification report, Ocul. Surf, 15, 3, pp. 276-283, (2017)
[6]  
Stevenson W., Chauhan S.K., Dana R., Dry eye disease: An immune-mediated ocular surface disorder, Arch. Ophthalmol, 130, 1, pp. 90-100, (2012)
[7]  
Zhu X., Topouzis S., Liang L., Stotish R.L., Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism, Cytokine, 26, 6, pp. 262-272, (2004)
[8]  
Niederkorn JY, Stern ME, Pflugfelder SC, De Paiva CS, Corrales RM, Gao J, Siemasko K, Desicating stress induces T cell-mediated Sjogren’ssyndrome-like lacrimal kerotoconjuctivitis, J. Immunol, 176, 7, pp. 3950-3957, (2006)
[9]  
Dursun D., Wang M., Monroy D., Li D.Q., Lokeshwar B.L., Stern M.E., Pflugfelder S.C., A mouse model of keratoconjunctivitis sicca, Invest. Ophthalmol. Vis. Sci, 43, 3, pp. 632-638, (2002)
[10]  
Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., Daniels T.E., Fox P.C., Fox R.I., Kassan S.S., Pillemer S.R., Talal N., Weisman M.H., Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group, Ann. Rheum. Dis, 61, 6, pp. 554-558, (2002)